Middle East gains breast cancer blood test
This article was originally published in Clinica
US company Power3 Medical Products has launched its breast cancer diagnostic blood test BC-SeraPro in 12 Middle Eastern countries. The Texas-based company (The Woodlands) expects the test to be performed in conjunction with mammography, and believes that it will help reduce the number of patients subjected to erroneous results from mammograms - which is allegedly 50% of women screened in the US.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.